Tofacitinib citrate is primarily used in the treatment of autoimmune and inflammatory conditions. It is effective in managing moderate to severe rheumatoid arthritis, especially in patients who have not responded well to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). The compound also shows efficacy in treating psoriatic arthritis and juvenile idiopathic arthritis. It is approved for use in ulcerative colitis, a type of inflammatory bowel disease, helping induce and maintain remission in adults with moderate to severe forms of the condition. Due to its mechanism of inhibiting Janus kinase (JAK), it modulates the immune response and reduces inflammation, making it useful in several immune-mediated disorders. Tofacitinib citrate is administered orally, offering a convenient alternative to biologic injectable therapies. Its use is generally reserved for specific patient populations due to potential side effects, including increased risk of infections, cardiovascular events, and blood clots. Ongoing research explores its potential in other inflammatory and autoimmune diseases.